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In human cervical carcinomas papillomavirus DNA is
frequently integrated in the cell genome. We have
cloned the integration site of human papillomavirus-18
DNA in human chromosome region 12q13–15 present in
the SW756 cervical carcinoma cell line. Viral DNA is
broken from nucleotides 2643 to 3418 in the E1 and E2
open reading frames, resulting in a deletion of 775 bases
of viral DNA. Cloning and sequence analysis of the rear-
ranged and germline alleles shows that there is no ho-
mology between the target cellular and viral DNA, sug-
gesting it is a nonhomologous recombination. The target
cellular region is called papillomavirus associated locus
2 (PAL2). The 5*- and 3*-flanking probes derived from the
hybrid viral-cellular clone detect completely different
germline restriction fragments in DNA from cells with
normal chromosome 12. There is no overlap between the
restriction maps of the target germline clones obtained
with 5*- and 3*-flanking probes. Probes from these germ-
line clones beyond the breakpoint position do not detect
any DNA rearrangement in SW756 cells DNA. These data
prove that there is a deletion of cellular DNA as conse-
quence of the integration, with an estimated minimum
size of 14 kilobases. Both cellular flanking probes are
outside the amplicon of this chromosome region identi-
fied in the OSA and RMS13 sarcoma cell lines, compris-
ing SAS-CHOP-CDK4-MDM2 genes and where transloca-
tion breakpoints are located in liposarcomas. The
integration at 12q13–15 might have been selected by its
contribution to the tumor phenotype.
Recurrent chromosomal alterations are a hallmark of many
types of tumors, and their cloning and characterization in
lymphoid tumors has been very instrumental in the identifica-
tion of oncogenic loci (1–3). In solid tumors, the characteriza-
tion of chromosome aberrations lags further behind. However,
specific translocations associated to specific types of solid tu-
mors are often identified (4–7) and are also likely to be related
to some aspect of tumor phenotype (8). These chromosomal
alterations are usually manifested as translocations, amplifi-
cations, deletions, or losses of heterozygosity. In virus-associ-
ated tumors, such as cervical carcinoma linked to papillomavi-
ruses and hepatocellular carcinoma linked to hepatitis B virus,
the integration of viral DNA represents an additional type of
DNA damage. This viral DNA integration can be considered an
alternative to translocations but with similar biological conse-
quences (9–11). Furthermore the viral DNA in these integra-
tion sites will provide a tag for their identification, cloning, and
characterization.
Human papillomaviruses have been associated with tumors
of genital and skin origin (12). There are more than 70 viral
DNA types, but two of them, HPV161 and HPV18, are linked to
over 70% of the cervical cancers (12). The mechanism by which
these viruses are implicated in oncogenesis is very complex and
has two main components. First of all, the oncogenic early viral
genes E7 and E6 are capable of interacting with the products of
RB (13) and P53 (14, 15) genes respectively, thus achieving a
functional inactivation of two cellular tumor suppressor genes.
However, E6 and E7 viral genes can also be expressed from
viral DNA in an episomal form (16). Second, most malignant
tumors of the genital tract have viral DNA integrated in the
cellular genome causing a genomic rearrangement (11, 12).
Nevertheless, these integrations are usually studied from the
consequences on viral genes (16) rather than on the cellular
genome; this latter aspect is the object of the present work.
Integration of HPV DNA does not form part of the viral life
cycle. The integration mechanism appears to be the result of
illegitimate recombination near DNase I hypersensitive sites
(17–19). The integrated viral DNA confers growth advantage to
the cell due to viral gene deregulation (20). Cytogenetic anal-
ysis of cervical carcinomas (21) shows that integrations are
clonal and that the viral DNA is located in some chromosomal
regions that have already been associated with other tumor
phenotypes (9, 10). The observation of clonal population is
likely to be the result of a strong selection for the biological
consequences of some integration events, thus their detection
in regions linked to the tumor phenotype (9, 10). These findings
are very similar to those already described for the role of
nontransforming retroviruses in oncogenesis (21), where the
most characteristic observation is the detection of common
sites of provirus insertion, an event known as insertional mu-
tagenesis, which are linked to a tumor phenotype (22).
Two human chromosomal regions, 8q24 and 12q13–15, are
common integration regions for papillomavirus DNA in genital
cancers. Both HPV-16 and HPV-18 DNA have been found in
the two regions (21–27). The cervical carcinoma SW756 cell line
has HPV type 18 DNA integrated in 12q13–15 (26, 28), and this
locus, called papillomavirus-associated locus 2 (PAL2), is the
object of the present report.
Human chromosomal region 12q13–15 undergoes several
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types of genetic alterations. Translocations and amplifications
have been found in melanoma (7), lipoma (29), liposarcomas (6,
30–32), gliomas (33), leiomyosarcomas (29, 34–36), pleomor-
phic adenomas (29), and lymphomas (37, 38). Integration of
hepatitis B virus DNA in this region has been reported in one
case of hepatocellular carcinoma (39), and integration of
HPV-16 DNA has been found in another cervical carcinoma cell
line, SK-v (27, 28).
The detection of such a variety of gross 12q13–15 chromo-
somal alterations suggests that this is a region likely to be rich
in genes related to the tumor phenotype (40), most of them
related to cell cycle control (41). Among them there are mem-
brane receptors and proteins like WNT1 and two members of
the transmembrane four superfamily of proteins, SAS and
ME491, which are implicated in the control of cell proliferation
(42); the antigen ME491/CD63 has been correlated with the
prognosis of melanoma (43). There are several genes coding for
proteins implicated in cell cycle regulation like CDK2 and
CDK4 (44) and for oncogenes likeMDM2, which interacts with
p53 (45). Genes coding for signal transduction molecules like
RAP1A and RAB5b and for transcription factors like GLI1,
CHOP, and ATF1. However, in most cases these genes have not
been linked to any specific tumor with the exception of trans-
locations affecting CHOP in liposarcomas resulting in a gene
fusion (6, 32, 47). Furthermore the 12q13–15 region is also
likely to contain a tumor suppressor gene based on data from
the detection of loss of heterozygosity in seminomas (48, 49),
gliomas (50), and prostate cancer, where the presence or ab-
sence of a fragment derived from region 12q13–15 determined
its oncogenic potential (51).
We report the cloning and characterization of PAL2, the
integration site of HPV-18 DNA in chromosome region
12q13–15 present in the cervical carcinoma cell line SW756
(26) as well as of the corresponding germline target sequences.
This viral-cellular DNA recombination is nonhomologous and
causes the deletion of cellular DNA and a small region of viral
DNA. The integration of HPV18 is not located in the area of
DNA amplification described in 12q13–15 in some sarcoma cell
lines. This is a genomic region likely to be implicated in the
tumor phenotype.
EXPERIMENTAL PROCEDURES
Cell Culture—The SW756 cell line was obtained from Dr. J. A.
DiPaolo, National Cancer Institute, Bethesda, MD. The cervical carci-
noma SW756, the colon carcinoma Colo320, and the rabdomyosarcoma
RMS13 cell lines were grown in Dulbecco’s modified Eagle’s medium
with 10% fetal calf serum. The MOLT4 T-cell lymphoma, the OSA
osteosarcoma (from O. Mykeblost, Oslo, Norway), and the Burkitt lym-
phoma cell lines (from G. Klein, Stockholm) were grown in RPMI 1640
supplemented with 10% fetal calf serum. All the other cell lines were
obtained from ATCC (Rockville, MD).
Probes—HPV18 genomic clone was provided by H. zur Hausen and
E. M. De Villiers (Heidelberg, Germany). CHOP probe, plasmid WT10,
was obtained from P. Aman (Lund University, Sweden). CDK2 and
CDK4 probes, plasmids pCDK2 and pCDK4, were from D. Beach (Cold
Spring Harbor Laboratory, Cold Spring Harbor, NY). MDM2 probe,
plasmid MDM2-FL5, was from B. Vogelstein (John Hopkins University,
Baltimore, MD). SAS probe, plasmid pSJP2, was from P. Meltzer (Na-
tional Center for Human Genome Research, National Institutes of
Health, Bethesda, MD). SP1 probe, plasmid pPacSP1, was from R. Tjian
(University of California, Berkeley, CA). RARg probe was from P.
Chambon (INSERM U184, Faculté de Medicine, Strasbourg, France).
WNT1 probe was obtained from the ATCC (Rockville, MD). The DNA
insert to be used as probe was isolated by restriction digestion and
purified with a Geneclean II kit (Bio 101, Inc., La Jolla, CA). The probes
were labeled using a commercial random priming kit from Amersham
Corp.
DNA and RNA Preparation and Analysis—DNA was prepared fol-
lowing standard procedures based on cell lysis and treatment with
proteinase K and ribonuclease A (52). Afterward, the DNA was cleaned
by repeated phenol and phenol-chloroform extractions (53). Digestions
with restriction enzymes were performed following manufacturer’s in-
structions (Promega or Boehringer Manheim) (52, 53). The digested
DNA was fractionated in an 0.8% agarose gel in Tris/sodium acetate/
EDTA buffer (52) with phage l DNA digested with HindIII or BstE2 as
size markers. The DNA was transferred to Hybond-N1 nylon mem-
branes (Amersham Corp.) and fixed by alkali treatment. RNA was
prepared by cell treatment like guanidinum thyocianate followed by
centrifugation in cesium chloride according to a standard protocol (54).
Hybridization of DNA to different probes was carried out in 5 3 SSC
(SSC is 0.15 M NaCl, 0.015 M sodium citrate), 0.1% SDS, at 65 °C for 18
h. The filters were washed in 2 3 SSC, 0.1% SDS at 62 °C for 15 min
followed by three washes in 0.2 3 SSC, 0.1% SDS at 62 °C for 20 min.
Northern blots were hybridized under the same conditions, except that
the high stringency washes were done at 55 °C (55). Quantitation of the
blots were performed using a densitometer from Bio-Rad.
Genomic Cloning—To clone the rearranged allele from SW756 cells
with integrated HPV18 DNA, 75 mg of cellular DNA were digested to
completion with EcoRI and fractionated in a sucrose gradient by cen-
trifugation (52). DNA fractions comprising the 10–15-kilobase pair
range were pooled and ligated to EcoRI-digested lDASH (Stratagene,
La Jolla, CA) arms phage vector purified by sucrose gradient
centrifugation.
To obtain human germline clones, we used a commercially available
human genomic library made by partial Sau3A digestion of DNA from
a 3-year-old Caucasian male and addition of EcoRI linkers, followed by
cloning in lFIXII vector (Stratagene, La Jolla, CA). This library was
screened with cellular DNA sequences flanking the integrated viral
DNA. Positive phage clones were partially digested with different re-
striction enzymes and mapped by hybridization to end-labeled T7 and
T3 primers. DNA fragments free of repetitive sequences were subcloned
in pBluescript SKII(2) plasmid and used for different studies as probes.
DNA Sequencing—The different clones in pBluescript SKII(-) vectors
were sequenced by the chain termination method using dideoxynucle-
otides with T7 DNA polymerase (Sequenase) from Amersham Corp. The
sequences have the following GenBank accession numbers: X88931 for
PAL2A and X88932 for PAL2B.
RESULTS
Cloning of HPV-18 DNA Integrated in the Genome of SW756
Cells—The SW756 cell line is derived from a cervical carcinoma
and contains HPV18 DNA integrated in the chromosome region
12q13–15 (26, 28). The integrated HPV18 viral DNA can be
identified as bands hybridizing to viral DNA generated by
enzymes that do not cut within the viral genome, like SalI,
XhoI, EcoRI, and HindIII. By restriction enzyme analysis and
hybridization to subgenomic viral probes, we first determined
that viral DNA breakpoint must be located between the HincII
sites at positions 2472 and 3605 (not shown). To clone the
integrated viral DNA, we made a library of EcoRI-digested
DNA from SW756 cells screened with a complete HPV18 DNA
probe. We obtained a 12.5-kb clone, l12QHP, that was mapped
with several restriction enzymes (Fig. 1) and hybridized to
subgenomic viral probes, confirming that the breakpoint of the
circular and extrachromosomal viral DNA before integration is
between the HincII restriction sites at the end of the E1 and
beginning of E2 ORFs. This clone lacks the internal EcoRI site
at nucleotide 2440 within the E1 ORF. The phage clone,
l12QHP, has cellular DNA in both flanks. From the l12QHP
clone, we prepared three cellular flanking probes. Two probes
were from the 59-flank; the pS3 probe is a 1.6-kb EcoRI-SpeI
fragment, and pHH probe is a 0.7-kb HindIII-HincII fragment
with some viral nucleotides near the HincII site. From the
39-end we prepared probe p500, which is an 0.5-kb HincII-
HincII fragment (Fig. 1) also with some viral nucleotides at one
end.
Flanking Cellular Probes Detect Different Genomic Regions
Suggesting a Deletion at the Integration Site—As a conse-
quence of the integration, there might be complex cellular DNA
rearrangements or deletions. To ascertain if both flanking
probes detected the same cellular genomic region, we deter-
mined the germline restriction pattern with both probes in
DNA from several cell lines. We used probe pS3 from the
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59-flank and probe p500 from the 39-flank. To develop this
pattern, we used a cell line, Ramos, that does not have any
alteration on chromosome 12. The pS3 (59) probe detects the
following bands, EcoRI (3.2 kb), HindIII (9.6 kb), XbaI (5.8 kb),
SacI (15 kb), ApaI (24 kb), BamHI (19 kb), KpnI (15 kb), and
SpeI (3 kb). The probe derived from the 39-flank, p500, detects
the following fragments: EcoRI (4.5 kb), HindIII (2.8 kb), XbaI
(6.9 kb), SacI (6.7 kb), ApaI (1.2 kb), BamHI (14 kb), KpnI (35
kb), and SpeI (30 kb). Probes pS3 (Fig. 2A) and p500 (Fig. 2B)
detected a completely different genomic region in all restriction
digestions performed. This observation suggests that the re-
gion detected by each probe is not overlapping and therefore
there is a deletion of cellular DNA as a consequence of the
integration of viral DNA in SW756 cells. The size of the dele-
tion is likely to be at least larger than 14 kb based on the size
of the observed restriction fragments.
Cloning the Target Germline Alleles—The genomic target
region corresponding to both flanks of the integration site were
obtained by screening a genomic library made from a healthy
individual. One clone, lh12/8HH, was obtained with probe S3
from the 59-flank. The clone is 18 kilobase pairs long and spans
the 59 breakpoint, of which approximately 6 kb were replaced
as result of HPV 18 integration (Fig. 3A). This part of the target
region is called PAL2A.
From the 39-end, two clones were isolated with probe p500,
lh12/32 and lh12/1–500, of 13 (not shown) and 17 kb, respec-
tively (Fig. 3B). These two clones are overlapping and cover a
total genomic region of 23 kb, of which 8 kb were lost as a result
of the integration. This side of the target region is called
PAL2B.
The comparison of restriction maps from clones lh12/8HH,
lh12/32, and lh12/1–500 shows no overlap between PAL2A (59)
or PAL2B (39) regions. These data support the conclusion of a
deletion of genomic DNA at the integration site, which has a
minimum size of 14 kb, and the cloned genomic region, which
has been replaced by viral DNA in the rearranged allele.
Internal Genomic Probes Detect Germline But Not Rear-
ranged Alleles—The use of cellular probes derived from the
germline clones corresponding to the region that has been
replaced by viral DNA should detect only the germline allele,
but not the rearranged one, if there is a deletion as a result of
HPV18 DNA integration. To confirm this interpretation, we
hybridized DNA from three cell lines, RMS13, OSA, and SW
756, with probes derived from the two phage germline clones,
lh12/8HH and lh12/1–500, in such a way that they are to both
sides of the breakpoints. The SW756 cell line has a 17-kb EcoRI
band that is detected with an HPV18 probe (Fig. 4A). The 59
breakpoint was examined with the pS3 probe and with probe
pXR, a 0.25-kb XbaI-EcoRI fragment (Fig. 3A) from the region
replaced by the viral DNA. The results for PAL2A, containing
the 59 breakpoint, are shown in Fig. 4, B and C. The 39 break-
point was studied with probes p500 and pRH, a 0.5-kb EcoRI-
HindIII fragment, from the region replaced by viral DNA (Fig.
3B). The results for the PAL2B region, containing the 39 break-
point, are shown in Fig. 4, D and E. The two probes retained in
FIG. 1. Structure of the phage clone containing the integrated
human papillomavirus type 18 DNA in the genome of SW756
cells surrounded by cellular sequences. The l12QHP clone was
isolated from a genomic library of SW756 cells and screened with
HPV-18 DNA. The thick line represents the region where DNA of viral
origin is located within the clone. The arrow indicates the start and
direction of transcription of retain viral early genes. Under the map, the
locations of several probes used in this work are indicated, pS3, pHH
from the 59-flank, and p500 from the 39-flank. R, EcoRI; Sp, SpeI; X,
XbaI; H, HindIII; Hc, HincII; B, BamHI; K, KpnI; A, ApaI. The restric-
tion sites were determined by partial digestion of the clone followed by
hybridization to labeled T3 and T7 oligonucleotide primers. The clone
was hybridized to viral subgenomic probes and to total human DNA to
detect fragments with repetitive sequences. The retained viral open
reading frames are indicated as well as the relative position of viral
genes. The breakpoints affect the E2 and E1 ORFs. The lcr is the viral
long control region where the origin of replication and several transcrip-
tion control sequences are located.
FIG. 2. Detection of different genomic cellular sequences
(PAL2) with flanking probes derived from the two ends of the
integrated viral DNA. Southern blots of cellular DNA from the Ramos
cell line with normal chromosome 12 digested with several restriction
enzymes and hybridized to cellular probe pS3 derived flanking the 59
breakpoint (A) or to cellular probe p500 flanking the 39 breakpoint (B).
FIG. 3. Structure of germline clones corresponding to flanks of
the integrated viral DNA. A, germinal clone, lh12/8HH, correspond-
ing to the 59 breakpoint and isolated with probe pS3. B, germinal clone,
lh12/1–500, derived from the 39 breakpoint obtained with probe p500.
The location of different probes used in this work are indicated. The
restriction map of the two overlapping clones is shown, with the relative
position of the probe used for their isolation, the cellular flanking probe
from the rearranged allele. In these clones, we have also determined the
presence of repetitive DNA sequences. The arrow represents the loca-
tion where the recombination between cellular and viral DNA took
place. R, EcoRI; X, XbaI; S, SacI; K, KpnI; A, ApaI; Sp, SpeI;H,HindIII.
The arrow indicate the location of the breakpoint and the separation
between retained and lost DNA.
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the hybrid clone, pS3 and p500, detect germline and rear-
ranged alleles (Fig. 4, B and D). The internal probes, from
replaced cellular DNA, pXR and pRH, only detect germline
alleles (Fig. 4, C and E), ruling out their retention as part of a
more complex rearrangement. These observations confirm the
interpretation of a cellular DNA deletion at the integration site
of HPV18 DNA in 12q13 between the regions defined by the
PAL2A and PAL2B loci.
HPV-18 DNA Integration Site Is Outside Known Amplicons
of Human 12q13–15 Region—There are two cell lines, OSA and
RMS13 with an amplicon in the 12q13–15 region (45). This
amplicon contains the region where most translocations occur
(29–33, 46). We determined if the cellular flanking probes are
located within these amplicons. For this purpose, we digested
DNA from five cell lines, Colo 320, MOLT4, OSA, RMS13, and
SW756 and hybridized them to the breakpoint flanking probes;
to probes from genes within the amplicon like CDK4 and SAS;
to probes from genes outside the amplicon like SP1, WNT1,
RARg, and CDK2; and to MDM2, which is within the OSA
amplicon but outside the RMS13 amplicon. Densitometric anal-
ysis of these Southern blots detected a 5-fold amplification of
the genes included within the amplicon. The results with these
cellular gene probes and with flanking probe pS3 are shown in
Fig. 5. The results with the other three PAL2 probes are shown
in Fig. 4, but only data for three cell lines is included in this
figure. These data demonstrate that both ends of the integra-
tion site in SW756 cell line, the PAL2A and PAL2B loci, are
outside the genomic region defined by the amplicons of both cell
lines, OSA and RMS13.
Sequence of the Cellular-Viral Junctions and Target Cellular
Sequences—The sequence of the viral cellular junctions in the
rearranged allele were determined and compared with the
cellular and viral sequences. We sequenced 761 nucleotides
from the germline PAL2A region (Fig. 6A). The cellular se-
quence spanning the 59 breakpoint does not contain repetitive
elements and is AT-rich. There is no DNA homology between
the viral and cellular target sequences. The 59 recombinant
breakpoint was sequenced from the cellularHindIII to the most
proximal viral HincII (probe pHH in Fig. 1) and occurs within
the early region E2 gene at nucleotides 3418 (not shown).
The germline sequence spanning the 39 breakpoint was ob-
tained from clone p500 and is shown in Fig. 6B. The sequence
comprising the 39 breakpoint was determined from the viral
HincII site (nucleotides 2643) to the most proximal cellular
HincII site in the hybrid clone (Fig. 1). The breakpoint of viral
DNA is located at nucleotide 2643 within the E1 ORF.
There was no significant homology between the viral DNA
and the sequence of the target alleles, PAL2A and PAL2B. A
search did not reveal any homology of the target sequences to
any known sequence in the GenBank data base.
The retained viral DNA has several point mutations in the
region proximal to the breakpoints with respect to the refer-
ence HPV18 DNA. In the 59 breakpoint 190 viral nucleotides
were sequenced, and we detected viral mutations at positions
3462 (A3T), 3533 (T3C), 3557 (C3A), 3577 (C3T), 3584
FIG. 4. Deletion of internal genomic probes in SW756 cells
DNA. 10 mg of DNA from OSA and RMS13 cell lines as reference for not
rearranged alleles and from SW756 cells were digested to completion
with EcoRI and fractionated in an 0.8% agarose gel. The DNA was
transferred to Hybond-N1 membranes and hybridized to different
probes. A, detection of rearranged allele with viral DNA detected by
hybridization to HPV-18 DNA. B, detection of rearranged and germline
alleles from the 59 breakpoint with flanking probe pS3. C, lack of
detection of 59 rearrangement of genomic DNA from the 59 genomic
clone with probe pXR, derived from the region replaced by viral DNA.D,
detection of rearranged and germline alleles with a probe from the
39-flank, p500. E, lack of detection of rearrangement of genomic DNA
replaced by viral DNA with probe, pRH, derived from the 39 genomic
clone.
FIG. 5. Relationship of integration site to two amplicons of
12q13 region. Both ends of the integrated viral DNA are outside the
amplicon of 12q13. EcoRI-digested DNA from five cell lines, Colo320,
Daudi, OSA, RMS13, and SW756 was hybridized to several probes from
genes located in 12q13, some of which, SAS and CDK4, are included in
both amplicons, and one, MDM2, is amplified only in the OSA cell line.
From the PAL2A locus, probe S3 was used. The probe used in each case
is indicated to the right side of the corresponding blot. In some blots, the
detection of several bands is due to the use of cDNA probes that contain
several exons.
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(A3C), and 3951 (T3G). In the 39 breakpoint, the small region
sequenced has mutations at positions 2482 (T3C), 2509
(G3A), and 2551 (G3T) and also in the EcoRI site within E1
ORF that is lost, but this mutation was only identified by the
loss of the restriction site and not by sequencing.
DISCUSSION
The detection of integrated HPV DNA in the host genome is
a common characteristic in cases of advanced cervical carci-
noma. This observation can therefore be considered a recurrent
type of genetic damage that could be selected for and thus
contribute to the tumor phenotype. This integration has two
different aspects. First, it can be looked at from the point of
view of the viral DNA. There might be a selection for or against
certain viral genes that will determine which viral genes are
retained and the position where the recombination will occur in
the viral genome. Thus, it is important to retain the genes that
would favor cell proliferation, like E6 and E7, and delete or
damage its repressor, E2, and that is what actually is observed
in SW756 (Fig. 1) and in other cervical carcinoma cell lines (17,
28, 53). Most of the work on the role of HPV integration has
been focused from this perspective (11, 28, 56). Furthermore,
the integrated viral genes might have an altered regulation as
a consequence of the cellular flanking sequences. Thus in
SW756 cells, the regulation by glucocorticoids of E6 and E7
gene expression is affected by the integration site (57). The
expression of the viral oncogenes might favor additional chro-
mosome instability that could be the cause of other genetic
defects not directly linked to the integration itself (58). Sec-
ondly, the integration chromosomal location might also be se-
lected for the effects on the host genome either by gene damage
or by a cis effect of viral sequences on nearby cellular genes
that might lead to a deregulated expression. Therefore, the
cellular genetic alteration resulting from viral DNA integration
is a potentially oncogenic event. In most of the cases, where the
chromosomal location has been mapped, like 8q24 or 12q13–15
(9), it is a genomic region already associated with the tumor
phenotype suggesting a possible role that has not yet been
demonstrated in cancer cases associated to DNA tumor viruses.
The limited evidence available is consistent with this view (9,
10), although that is a common observation in oncogenesis by
nontransforming retroviruses (22).
In this report, we have shown in the SW756 cervical carci-
noma cell line that the viral integration has resulted in a
deletion of viral and cellular DNA, at chromosome region
12q13–14. Three types of evidence support this interpretation.
There are completely different restriction patterns in germline
PAL2A and PAL2B DNA hybridized to cellular probes derived
from both flanks on the integrated viral DNA (Fig. 2); there is
no overlap between PAL2A and PAL2B genomic clones derived
from both ends (Fig. 3), and there is lack of detection of rear-
ranged allele by cellular probes from the cellular region re-
placed by viral DNA (Fig. 4). This integration is a likely con-
sequence of nonhomologous recombination because of the lack
of any significant homology between viral and cellular se-
quences. The location of the break within the viral genome and,
probably, the chromosomal location are likely to be the result of
strong biological selection for them. It is interesting to note the
large differences in deleted DNA, 0.775 kb for viral DNA and
more than 14 kb of cellular DNA. Although the deleted cellular
DNA is likely to be much larger based on cytogenetic data,
partial loss of a band occurs in the 12q13–15 region (25). The
discrepancy between the sizes of cellular and viral deleted DNA
might be explained as the result of illegitimate recombination
between viral DNA and a loop of chromosomal DNA. The cel-
lular DNA, due to its highly organized superstructure, might
have in close proximity two distant regions; in this DNA, the
viral DNA recombines by forming a bridge between the two
distal ends of the loop and results in deletion of the intervening
cellular DNA. The DNA sequence at the viral-cellular junctions
(Fig. 6) shows no significant homology, suggesting that it is a
nonhomologous recombination (59) in agreement with other
cases of recombination between HPV and cellular DNA (60).
The lack of any significant homology between viral DNA and
the two target, PAL2A and PAL2B, sequences at the integra-
tion site and the subsequent observation of its localization in
chromosome regions associated to the tumor phenotype, like
the case of PAL1 in 8q24 (55) strongly suggest that there is a
strong biological selection for some chromosomal locations.
This selection is more likely to be related to the properties of
this chromosomal region than to the retention of some viral
genes, like E6 and E7. The expression of E6 and E7 could be
achieved from almost any position where they might integrate
in so far as they are structurally intact. If that was the case,
there would be no reason to expect the integrations to be
located in oncogenic regions.
The location of the integration in the SW756 cell line maps to
a genomic region implicated in several oncologic phenotypes.
The type of alteration includes both translocations and ampli-
fications. Most recurrent chromosomal alterations contribute
to the tumor phenotype by altering a gene. This gene modifi-
cation can be very heterogeneous, ranging from its overexpres-
sion to changes in regulation, mutations, or deletions. The type
of modification depends on the biological function of the gene.
Thus the so called oncogenes are deregulated or overexpressed,
or their products are altered while tumor suppressor genes
undergo inactivating alterations, like mutations or deletions.
Deletion of cellular sequences is a characteristic observation
in genetic alterations of tumor suppressor genes. There are
three lines of evidence pointing to the existence of a tumor
FIG. 6. Nucleotide sequence of germline target sequence at
both ends of integration site of HPV18 DNA in SW756 cells. A,
nucleotide sequence of the PAL2A germline spanning the 59 cellular-
viral recombination breakpoint in the hybrid clone described in Fig. 1.
B, nucleotide sequence of the germline PAL2B region spanning the
viral-cellular recombination breakpoint corresponding to the 39 in the
integration site described in Fig. 1. The location of each of the break-
points is indicated by an arrow. The deleted cellular DNA that is
replaced by viral DNA in the recombinant clone is indicated in boldface
characters. The accession numbers are X88931 and X88932 for PAL2A
and PAL2B respectively.
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suppressor gene in the 12q13–15 region. The first is loss of
heterozygosity in 40% of male germ cell tumors (48) and in
glioblastomas (50). Furthermore, in a prostate cancer cell line
containing a deletion in this region, the malignant phenotype
could be reversed after introduction of a normal chromosome
12, and the malignant phenotype reappeared following the loss
of the introduced chromosome (51). The deletion detected by
HPV-18 integration might be an indicator of the location of this
putative suppressor gene, which is also known to be outside the
OSA and RMS13 amplicons in the 12q13–15 (49).
This human region is syntenic with regions of mouse chro-
mosomes 10 and 15 (40). The amplified genes in OSA and
RMS13 cell line are all located in the region that is syntenic
with mouse chromosome 10 (40). The data on the amplicons in
different cell lines combined with data from translocation
breakpoints in different types of tumors suggests the following
gene order in this region: COL2A1-WNT1-ATF1-GPDH-SP1-
RARg-A2MR-GLI (40). The region amplified in OSA and
RMS13 comprises A2MR-GLI-MDM2-ERB3-GST3 and CHOP,
but it does not include RARg, SP1, orWNT1 (33, 45). Thus, the
lack of amplification of PAL2 places it in a region outside this
gene cluster (25). The precise location of PAL2 will be deter-
mined when the yeast artificial chromosome containing it is
isolated and placed within the existing map of the region.
HPV integration was postulated to be a late event in the
process of oncogenesis by human papillomaviruses (61). During
the early steps of the oncogenic process by HPV, the extra-
chromosomal location of the E6 and E7 viral genes is enough to
generate an expanding population, because of cell cycle dereg-
ulation, where additional genetic alterations might occur. In
cervical carcinoma, there are frequent rearrangements of re-
gion 11q13 not linked to HPV (5). Some of these additional
genetic alterations might be the consequence of viral DNA
integration. If the integration happens in an oncogenic region,
it is likely to be selected for its contribution to some aspects of
the tumor phenotype, which are unlikely to be related to the
initial steps of transformation. In this case, the viral E6 and E7
contribute to expand the cells carrying important oncogenic
mutation (5). The detection of PAL1 in 8q24 (55) and PAL2 in
12q13–15 is consistent with this view. But their role in the
tumor phenotype will only be known when the implicated genes
are identified.
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